Merck & Co., Inc. (MRK) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Merck & Company, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.255 Thank you for standing by. Welcome to the Merkin Company, Inc., Raleigh, New Jersey, 00:00:04.255 -- 00:00:07.579 USA, fourth quarter sales and earnings conference call. 00:00:07.579 -- 00:00:10.922 At this time, all participants are in a listen-only mode until the question and answer 00:00:10.922 -- 00:00:13.265 session of today's conference. 00:00:13.265 -- 00:00:17.689 At that time, if you'd like to ask a question, you may press star 1 on your phone and 00:00:17.689 -- 00:00:21.253 record your name at the prompt. This call is being recorded. 00:00:21.253 -- 00:00:23.575 If you have any objections, you may disconnect at this time. 00:00:23.575 -- 00:00:26.678 I would now like to turn the conference over to Mr. 00:00:26.678 -- 00:00:29.809 Peter Danbaum. Senior Vice President, Investor Relations. 00:00:29.809 -- 00:00:30.631 Sir, you may begin. 00:00:30.631 -- 00:00:33.736 Thank you, Shirley, and good morning, everyone. 00:00:33.736 -- 00:00:37.662 Welcome to the fourth quarter 2025 conference call from Merck and Company Incorporated, 00:00:37.662 -- 00:00:42.630 Raleway, New Jersey, USA. Speaking on today's call will be Rob Davis, Chairman and Chief 00:00:42.630 -- 00:00:46.877 Executive Officer, Caroline Litchfield, Chief Financial Officer, and Dr. 00:00:46.877 -- 00:00:51.416 Dean Lee, President of Research Labs. Before we get started, I'd like to point out that 00:00:51.416 -- 00:00:54.881 we have items in our GAAP results, such as acquisition-related charges, restructuring 00:00:54.881 -- 00:00:58.506 costs, and certain other items that we have excluded from our non-GAAP results. 00:00:58.506 -- 00:01:01.310 There is a reconciliation in our press release. 00:01:01.310 -- 00:01:04.455 I will also remind you that some of the st...